Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction
- PMID: 22130116
- DOI: 10.1038/clpt.2011.271
Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction
Abstract
Cholesteryl ester transfer protein (CETP) inhibition is a promising experimental strategy to raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This review focuses on the highly selective and potent CE TP inhibitor anacetrapib and discusses the available preclinical and clinical information pertaining to it. We also describe strategies to target HDL-C, discuss the mechanism underlying CETP inhibition and its effects on lipid biology, and give an overview of other CETP inhibitors that are currently in development.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources